From WisPolitics.com/WisBusiness.com …
— Exact Sciences had $878 million in revenue in the fourth quarter of 2025, marking a 23% increase over the same period of 2024.
The Madison-based diagnostics company recently released its latest financial performance figures, which shows revenue from screening alone was $695 million for the quarter, an increase of 26% over the year. It also had $183 million in precision oncology revenue, up 14% on a reported basis.
Looking at the year overall, the business reports $3.25 billion in 2025 revenues, touting an 18% increase. That total included $2.53 billion in screening revenue and $717 million in precision oncology revenue.
Meanwhile, fourth-quarter net loss was $86 million, compared to $49.8 million in the fourth quarter of 2024. For the full year, net loss was $208 million, which Exact Sciences says is an improvement of $821 million.
Exact Sciences Chairman and CEO Kevin Conroy noted the company launched three new tests in 2025 while screening more people for cancer and guiding more personalized treatment decisions. In a statement on the financial report, he said momentum is building for the business.
“Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally,” he said.
See the release below.
Top Stories
– Clinics Sour on CMS After Agency Scraps 10-Year Primary Care Program Only Months In
– Should Drug Companies Be Advertising to Consumers?
– RFK Jr.’s allies are trying to free anti-vaccine doctors to speak their minds
– RFK Jr. regulators to weigh processed ingredients’ safety
– US could take action including fines against Hims after brief Wegovy copy launch
Press Releases
– Exact Sciences: Announces record fourth quarter and full year 2025 results
– Marshfield Clinic: Wisconsin Rapids hospital to open March 1
